MD

Business Context and Reporting Period

Company: Pediatrix Medical Group, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Overview: Pediatrix is the nation's largest health care services company focused on physician services for newborn, maternal-fetal, and other pediatric subspecialty care. The company operates a national network of approximately 776 affiliated physicians providing clinical care in 31 states and Puerto Rico, primarily within hospital-based Neonatal Intensive Care Units (NICUs). The company also operates the nation's largest private provider of newborn metabolic screening and hearing screening services.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net patient service revenue increased 12.4% to $619.6 million. This was driven by $37.6 million in revenue from acquisitions (12 physician groups) and $30.8 million in same-unit growth.
• Profitability: Net income increased 16.6% to $98.3 million. Operating margin improved by 38 basis points to 25.2%, primarily due to a reduction in general and administrative expenses as a percentage of revenue.
• Payor Mix Shift: The government component (principally Medicaid) of the payor mix increased to 27% in 2004 from 25% in 2003. This shift resulted in lower average reimbursement rates and increased contractual adjustments.
• Liquidity: Cash and cash equivalents decreased significantly from $27.9 million to $7.0 million. This was due to $150 million in common stock repurchases, $64.9 million in acquisition costs, and $54 million in net borrowings under the line of credit.
• Acquisitions: The company acquired 12 physician group practices in 2004, including eight neonatal, two pediatric cardiology, one maternal-fetal, and one pediatric intensive care practice.

Guidance, Outlook, Risks, and Contingencies

• Outlook: Management anticipates investing $50 million to $60 million in acquisitions during 2005. Funds for working capital and acquisitions are expected to be generated from operations and the $150 million revolving credit facility.
• Government Investigations: The company is subject to active and ongoing investigations by the Federal Trade Commission (FTC) regarding competition issues related to its 2001 acquisition of Magella. Additionally, federal and state authorities are investigating billing practices for Medicaid and TRICARE programs. Management cannot predict the outcome or potential financial impact of these investigations.
• Regulatory Risks: The company faces risks related to changes in government reimbursement rates, potential reductions in Medicaid funding, and compliance with complex federal and state fraud and abuse laws (e.g., Anti-Kickback Statute, Stark Law).
• Accounting Changes: The company will adopt FAS 123R (Share-Based Payment) effective July 1, 2005, which will require expensing stock-based compensation and is expected to have a significant impact on future results of operations.
• Insurance: Professional liability insurance premiums are expected to increase significantly, and the company is reviewing coverage options which may include higher self-insured deductibles.

Key Facts for Investor Verification

• Stock Repurchases: Verify the impact of the $150 million stock repurchase program completed in 2004 on future liquidity and capital allocation strategy.
• Investigation Status: Monitor the status and potential financial penalties associated with the ongoing FTC antitrust investigation and federal/state Medicaid billing inquiries.
• Payor Mix Sensitivity: Assess the financial impact of the increasing reliance on government payors (Medicaid), which reimburse at lower rates than commercial payors.
• Acquisition Integration: Evaluate the success of integrating the 12 physician groups acquired in 2004 and the pipeline for the planned $50-$60 million in 2005 acquisitions.
• FAS 123R Impact: Review the company's disclosure regarding the estimated impact of adopting FAS 123R on net income starting in the second half of 2005.